Clinical Trial Update: Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 study assessed the diagnostic performance of the PET tracer [18F]CTT1057 for PSMA-positive tumor detection, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• [18F]CTT1057 (CTT1057)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasms, Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2024-12-18